Completed
PHASE1
INTERVENTIONAL
NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC.
Primary Outcomes
Measure:
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
TimeFrame:
Predose up to 30 days postdose
Description:
PK: AUC0-∞ of LY3437943
Measure:
PK: Maximum observed concentration (Cmax) of LY3437943
TimeFrame:
Predose up to 30 days postdose
Description:
PK: Cmax of LY3437943
Trial Information
NCT ID
NCT05916560
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025